2 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Kure Cells, INC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma Administration of CAR T-cells at 3 different dose levels - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | Not yet recruiting | Kure Cells, INC | 12 | 2026-09-01 | 2026-05-28 |
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
PMID 10613347, PMID 27511158, PMID 30592986, PMID 32055000, PMID 35190680, PMID 36762851, PMID 37272512